Jose Nativi-Nicolau1, Mathew S Maurer2. 1. University of Utah, Salt Lake City, Utah. 2. Columbia University Medical Center, New York, New York, USA.
Abstract
PURPOSE OF REVIEW: The present article provides an update about the recent advances in the diagnosis and management of the most common types of cardiac amyloidosis, including light chain, wild-type transthyretin (ATTRwt), and mutant transthyretin (ATTRm). RECENT FINDINGS: The document reviews the utility of diagnostic tools including innovative echocardiographic indices, magnetic resonance T1 mapping and measurement of extracellular volume, and the role and validation of bone scintigraphy for the noninvasive assessment of ATTR amyloidosis. It summarizes the data about therapies for light chain amyloidosis including bortezomib regimens and also novel disease modifying therapies for ATTR amyloidosis such as gene silencers, transthyretin stabilizers, and degraders of amyloid fibrils. SUMMARY: The present review provides the readers with the necessary tools in order to recognize and diagnose cardiac amyloidosis early and introduces the recent advances in management that are improving the outcomes of a condition that was considered to be untreatable.
PURPOSE OF REVIEW: The present article provides an update about the recent advances in the diagnosis and management of the most common types of cardiac amyloidosis, including light chain, wild-type transthyretin (ATTRwt), and mutant transthyretin (ATTRm). RECENT FINDINGS: The document reviews the utility of diagnostic tools including innovative echocardiographic indices, magnetic resonance T1 mapping and measurement of extracellular volume, and the role and validation of bone scintigraphy for the noninvasive assessment of ATTRamyloidosis. It summarizes the data about therapies for light chain amyloidosis including bortezomib regimens and also novel disease modifying therapies for ATTRamyloidosis such as gene silencers, transthyretin stabilizers, and degraders of amyloid fibrils. SUMMARY: The present review provides the readers with the necessary tools in order to recognize and diagnose cardiac amyloidosis early and introduces the recent advances in management that are improving the outcomes of a condition that was considered to be untreatable.
Authors: Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Abdel-Rahman Torky; Marios Matiakis; Mammad Mammadov; Hannes Melnyk; Alexander Vogt; Renato de Vecchis; Boris Bigalke; Walter Wohlgemuth; Sophie Mavrogeni; Michel Noutsias Journal: Heart Fail Rev Date: 2019-07 Impact factor: 4.214
Authors: Santiago Decotto; Eugenia Villanueva; Diego Pérez de Arenaza; Elsa M Nucifora; María A Aguirre; María L Posadas-Martínez; Ricardo G Marenchino; César A Belziti Journal: Arch Cardiol Mex Date: 2022-07-01
Authors: A Yilmaz; J Bauersachs; F Bengel; R Büchel; I Kindermann; K Klingel; F Knebel; B Meder; C Morbach; E Nagel; E Schulze-Bahr; F Aus dem Siepen; N Frey Journal: Clin Res Cardiol Date: 2021-01-18 Impact factor: 5.460
Authors: Morie Gertz; David Adams; Yukio Ando; João Melo Beirão; Sabahat Bokhari; Teresa Coelho; Raymond L Comenzo; Thibaud Damy; Sharmila Dorbala; Brian M Drachman; Marianna Fontana; Julian D Gillmore; Martha Grogan; Philip N Hawkins; Isabelle Lousada; Arnt V Kristen; Frederick L Ruberg; Ole B Suhr; Mathew S Maurer; Jose Nativi-Nicolau; Candida Cristina Quarta; Claudio Rapezzi; Ronald Witteles; Giampaolo Merlini Journal: BMC Fam Pract Date: 2020-09-23 Impact factor: 2.497